SEC Tracker
Get the app

Naploy NPLY

Naploy Q2 FY25: revenue $2K; diluted EPS $0.00

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Naploy reported for Q2 FY25, the quarter ended Jan 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$2KAgainst $0 in Q2 FY2410-Q income statement, on EDGAR
  2. Net income−$3KAgainst −$6K in Q2 FY2410-Q income statement, on EDGAR
  3. Diluted EPS$0.00Against $0.00 in Q2 FY2410-Q income statement, on EDGAR
  4. Cash and cash equivalents$27K+3598% from $743 in Q2 FY2410-Q balance sheet, on EDGAR
  5. Cash from operations−$317Against −$4K in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Naploy files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (8000) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Medical Exercise MDXR
  2. Medicale MCLE public float $490K, Mar 31, 2025, over 18 months old
  3. Welsis WLSS public float $2M, Mar 31, 2025, over 18 months old
  4. Agape ATP ATPC public float $5M, Dec 31, 2025
  5. Longduoduo LDDD public float $9M, Dec 31, 2025